The letter highlights the strong scientific evidence supporting the safety and effectiveness of vaccines and underscores the role of the Vaccine Injury Compensation Program (VICP) in providing no-fault compensation for rare vaccine-related injuries. It emphasizes maintaining rigorous evidentiary standards and established processes for determining covered injuries, warning that adding a large number of conditions without sufficient scientific support could overwhelm the program, delay valid claims, and jeopardize its ability to function effectively and sustain access to vaccines.
To The Administration
Group letter to HHS urging the Sustainability of the Vaccine Injury Compensation Program (VICP)
- Topics: Access, Innovation
Related Letters & Comments
HLC drives policy change through strategic letters, comments, and reports that promote private-sector innovation. Focused on priorities like Medicare reform, telehealth, and health equity, HLC engages with lawmakers and agencies to shape a smarter, more responsive healthcare system.
To The Administration
Group letter to CMS opposing proposed remote monitoring restrictions in the 2027 Physician Fee Schedule
HLC also joined a coalition letter urging CMS not to finalize proposed changes to remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) in the 2027 Physician Fee Schedule proposed rule that would restrict clinically integrated …
To Congress
Group letter to the Committee on Education and Workforce urging House passage of S. 2120, the Older Americans Act (OAA) Reauthorization Act
HLC joined the Healthy Aging Coalition in urging the House to pass S. 2120, the Older Americans Act Reauthorization Act, following its bipartisan passage in the Senate. The letter emphasizes the importance of aging-network services, including nutrit…
To Congress
HLC response to Senate Finance Committee Democrats’ RFI on Drug Pricing
HLC urged Congress to preserve incentives for continued biopharmaceutical innovation while pursuing solutions that improve affordability for beneficiaries. The letter raised concerns about proposals to expand Medicare drug price negotiation and impo…
